Articles tagged with Breast Cancer Cells
Researchers at MIT have developed a synthetic gene circuit that can trigger the immune system to target cancer cells. The circuit is designed to detect two specific cancer markers and only activates a therapeutic response when both are present, offering new pathways for cancer immunotherapy.
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth. Repressing ammonia metabolism stunts tumor growth in mice.
For-Robin's monoclonal antibody JAA-F11 successfully targets and kills human breast cancer cells in human tumors grafted into mice, effectively treating triple-negative breast cancer. The company is now focusing on fundraising and preparing for human clinical trials to bring its product from the bench to the bedside.
The Translational Genomics Research Institute has developed novel processing methods for single-cell RNA sequencing, enabling researchers to identify genetic sources of diseases and tailor treatments. This breakthrough is crucial for understanding cancer and improving patient care.
Scientists studying cone snail venom aim to develop new medicines by understanding how the poison works. Researchers have discovered that cone snail toxins can overlap between the immune and central nervous systems in humans, potentially leading to breakthroughs in treatments for neurological diseases like Alzheimer's.
Researchers at UCLA have developed a new method called quantitative deformability cytometry (q-DC) to rapidly determine a single cell's stiffness and size. This technique allows for standardized measurements of single cells and could lead to improved cancer treatments by tracking patient progress and predicting drug effectiveness.
University of Minnesota researchers report a novel encapsulation approach to identify and maintain dormant cancer cells in a quiescent state. This method involves immobilizing cells within a rigid silica-PEG matrix, which prevents movement and proliferation, allowing for differential response between cancer cell lines.
Researchers at Trinity College Dublin found that rogue messengers released by cancer cells can suppress the body's immune system, making it harder to fight cancer. The discovery may lead to a blood test to identify patients most susceptible to treatment resistance, allowing for personalized treatment options.
Researchers at RUDN University discovered a redox-dependent mechanism that enables ovarian and breast cancer cells to resist chemotherapy. The mechanism involves the expression of genes encoding thioredoxin and peroxiredoxin, which play a crucial role in the antioxidant defense system.
A new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. The labyrinth chip is already in use in a breast cancer clinical trial, enabling doctors to plan customized treatments and monitor genetic changes.
Scientists at the University of Freiburg have developed a new model to isolate and study cancer stem cells from breast cancer patients. The team found that inhibiting the epigenetic regulator KDM4 can block proliferation of cancer stem cells, induce changes in their molecular make-up, and reduce tumor growth.
A team of researchers developed a tiny microfluidic device to track the long-term evolution of invasive cancer cells. The device allowed them to cultivate cells for up to three weeks, providing valuable insights into the biology of aggressive cells and potential targets for therapy.
Researchers create biocompatible degradable structures using stereolithography with sodium alginate precursor solutions, allowing for transient structures to dissolve away on demand. This technique is useful for making lab-on-a-chip devices and dynamic environments for live cells experiments.
A new Michigan State University study found that a protein released from visceral fat can cause non-cancerous cells to become cancerous. Abdominal obesity is associated with an increased risk of certain cancers, and body mass index may not be the best indicator of risk.
Researchers found that claudin-low triple negative breast cancers have high levels of regulatory T-cells, which suppress the immune system's defenses. They developed a strategy to deplete these cells, combining it with checkpoint inhibitors to slow tumor growth and improve outcomes.
A study has identified a genetic signature linked to defects in the DNA damage repair-genes BRCA1 and BRCA2 in breast cancer. The researchers found that this signature is not exclusive to BRCA mutations but also indicates other ways of deactivating the DNA repair mechanism, offering new insights into breast cancer treatment decisions.
Researchers found that formaldehyde, a toxin, is also used to fuel the one-carbon cycle in cells, producing DNA and amino acids. This discovery could lead to new cancer therapies by targeting this pathway.
A novel lineage-restricted stem cell was identified in the mammary gland, maintaining ER+ lineage expansion during pubertal development and long-term renewing capacities in adult mice. This finding challenges the current model of cellular hierarchy governing tissue development and maintenance.
Scientists have found that breast cancer cells spread to other parts of the body relatively late in disease development. This discovery supports the importance of early diagnosis and treatment, which can increase the chances of preventing cancer cell spread and improving survival rates.
Researchers identified synthetic lethal interactions that inhibit tumor growth in mesenchymal cells, a promising approach for treating alternative lengthening telomere (ALT) cancers. Simultaneous inhibition of BLM and FANCM genes could lead to more effective treatment with fewer side effects.
A recent University of Alberta study found that irradiation of breast fat can trigger an inflammatory response in cancer patients, enabling cancer cells to survive. The research team is developing an experimental autotaxin inhibitor to counteract this effect and improve radiotherapy's effectiveness.
Researchers at UCI have developed a stem cell-based method that selectively targets and kills cancerous tissue while preventing side effects. By identifying unique physical properties of cancer cells, the treatment enables targeted therapy, reducing harm to healthy tissue.
A CU Cancer Center study found that retinoic acid may fail against breast cancer cells marked by protein CK5 due to progesterone's promotion. Treatment timing might be crucial in preventing the growth of these dangerous cells.
Researchers found that age is the most strongly associated breast cancer risk factor with normal breast DNA methylation differences. The study characterized molecular differences in healthy tissues that may contribute to cancer risk, providing insight into how epigenetic dysregulation contributes to breast cancer.
Researchers discovered that CD44s plays a key role in sustaining EGFR signaling in glioblastoma multiforme, allowing cancer cells to survive. Removing CD44s from the cell surface reduces the growth of glioblastoma cells and increases sensitivity to erlotinib treatment.
Researchers from the University of Pennsylvania School of Medicine identified a process where cancer cells instruct normal cells to act like viruses, enabling tumors to spread and resist treatment. This 'virus mimic' is detected in the blood of cancer patients and could explain why some breast cancers are more aggressive than others.
Researchers at University of Missouri found that hormone replacement therapies can induce growth and metastasis in breast cancer by enriching specialized cancer cells like stem cells. The study suggests targeting these rare cells and immunotherapies to combat the disease.
Researchers have discovered that inhibiting 20-HETE, an acid metabolite overexpressed in cancer cells, reduces breast cancer tumor size and ability to spread. The study found that the drug HET0016 blocks key pathways that enable cancer cells to create a distant microenvironment.
Researchers developed an engineered opsonin protein to capture CTCs in the bloodstream, reducing detection time and increasing efficiency. The technology shows promise for improving cancer diagnostics by targeting specific carbohydrate molecules on CTCs.
Researchers identified 'clathrin-coated pits' as a new mechanism involved in cancer cell migration. These structures allow cancer cells to attach to surrounding collagen fibers and move around.
Researchers at Université de Genève discovered that healthy fibroblasts surrounding breast cancer cells have a unique variant of the estrogen receptor GPER in their nuclei. This genetic variation promotes tumor cell migration and invasiveness through the secretion of molecules that stimulate malignant growth.
Researchers discovered a mechanism that makes lung cancer cells dependent on mutated versions of the p53 gene, opening the potential for new treatments. They also showed that ChK1 inhibitors could effectively stop cancer cell multiplication in patients with gain of function p53 mutations.
Researchers found that metastatic breast cancer cells signal neighboring cells through the GLI transcription factor, allowing otherwise anchored cells to metastasize. The discovery highlights a promising link in the hedgehog signaling pathway, which can be targeted to reduce metastatic potential.
Scientists have identified a type of protein called Proline-Rich Homeodomain (PRH) that can help suppress the growth of breast cancer tumors. Monitoring PRH levels or activity in patients with breast cancer could be crucial for determining their prognosis.
Drexel University researchers uncover a crucial role of the Rad52 protein in RNA-dependent DNA repair. The study reveals an unexpected function of Rad52, promoting 'inverse strand exchange' between double-stranded DNA and RNA molecules. This mechanism may help identify new therapeutic targets for cancer treatment.
Scientists at IBS create nanostructures that function as channels for iodide transport in cell membranes, offering a new approach to diagnose and treat iodide transport disorders. The newly developed synthetic ion channels, called porphyrin boxes 1A (PB-1A), selectively allow the passage of negatively-charged ions, such as iodides.
University of Guelph researchers discover Ruby Ring onion variety has highest levels of quercetin and anthocyanin, compounds known for their anti-cancer properties. The study reveals red onions can activate pathways that encourage cancer cell death and disrupt communication between cells.
A study published in Cell found that exposure to common aldehydes can break down DNA repair mechanisms, increasing cancer risk. People with faulty BRCA2 genes are particularly sensitive to this damage, as these chemicals trigger the degradation of BRCA2 protein.
Researchers identified BPTF as a protein essential for mammary stem cell maintenance and found that removing or inhibiting it causes stem cells to differentiate and die. This discovery provides hope for developing a drug that targets BPTF in breast cancer cells, potentially leading to the differentiation and death of these cells.
Moffitt researchers demonstrate that mathematical models can be used to predict how different tumor cell populations interact with each other and respond to environmental changes. By applying small biological forces, they show that complex systems like cancer can be steered into a less invasive growth pattern.
A recent study published in Nature Cell Biology identified a small RNA molecule, miR-199a, that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The microRNA promotes particularly deadly forms of breast cancer and inhibiting its effects could improve existing breast cancer therapies.
A study published on Nature Communications reveals that breast cancer cells undergo a stiffening state prior to acquiring malignant features and becoming invasive. This discovery identifies a new signal in tumor cells that can be further explored when designing cancer-targeting therapies.
Researchers discovered that residual tumor cells display alterations in fat metabolism and oxidative stress, which contribute to DNA damage and cancer relapse. Targeting metabolic pathways in these cells could potentially prevent recurrence.
Researchers at EMBL found that residual breast cancer cells have specific traits that distinguish them from healthy cells and seem to cause relapse. The study suggests lipid metabolism as an exciting therapeutic target to reduce breast cancer recurrence.
A team of scientists has discovered that breast cancer cells rely on a different nutrient metabolism to produce energy than normal cells and non-metastasizing cancer cells. Inhibiting this process reduces metastases by over 60% in mouse models.
Researchers identified RIOK1 as a potential new target for cancer therapy that slows down disease progression by blocking its enzymatic activity. The study found that inhibiting RIOK1 can reduce the growth and aggressiveness of cancer cells, including those with mutated RAS proteins.
A study published in Scientific Reports found that strawberry extract inhibited the proliferation of breast cancer cells in both in vitro and in vivo models. The extract reduced cell viability, blocked cell division, and inhibited migration, while also stimulating the expression of a gene that suppresses metastasis.
Scientists have discovered that cancer can commandeers immature immune cells, called MDSCs, to facilitate its spread. MDSCs are normally part of the immune system's anti-tumor response but, under the influence of tumor-secreted cytokines, they can help tumors grow and metastasize.
A team of researchers at the University of Iowa documented how melanoma cells form tumors in a 3D model, finding similarities with breast tissue cancer cells. They identified two drugs, anti-beta 1 integrin/(CD29) and anti-CD44, that block tumor creation in both types of cancer.
Exposure to BPS multiplies breast cancer cells, exhibiting estrogen-mimicking behavior, and may cause breast cancer to become more aggressive. The study confirms BPS as a potent endocrine disruptor.
Researchers at Tel Aviv University find that modifying specific proteins during cell division unleashes a natural killing mechanism that targets rapidly proliferating cancer cells. The discovery may lead to the development of new treatments for aggressive cancers, including pancreatic and triple negative breast cancer.
Researchers at UC Berkeley have created a microfluidic device that can analyze individual tumor cells for specific cancer protein biomarkers. This technology could allow doctors to monitor treatment response through regular blood draws, potentially leading to more precise cancer diagnoses.
A new study by Johns Hopkins scientists reveals that nearly two-thirds of cancer mutations are caused by random DNA copying errors. The researchers developed a mathematical model based on DNA sequencing and epidemiologic data, estimating that 66% of cancer mutations result from copying errors.
Researchers at Cincinnati Children's Hospital Medical Center identify two signaling proteins, c-Fos and Dusp1, that make cancer cells resistant to chemotherapy. Blocking these proteins along with chemotherapy eliminates human leukemia in mouse models, suggesting a possible cure for certain types of kinase-driven cancers.
Researchers at the University of Bradford have developed a peptide that blocks RAN protein and kill cancer cells. The new treatment uses nanoparticles to deliver the peptide directly into cancer cells, showing promising results in lab tests.
A new study published in Nature Cell Biology reveals that the SHANK protein plays a crucial role in preventing the spread of breast cancer cells by regulating cell adhesion. The research also found that gene mutations in SHANK are linked to autism, demonstrating the protein's importance in both brain development and tumor invasion.
Researchers discovered that a metabolic enzyme called AKR1B1 drives aggressive basal-like breast cancer progression. An inhibitor of this enzyme, epalrestat, was shown to block the growth and metastasis of human basal-like breast cancer cells.
Scientists at the University of Alberta have developed synthetic DNA motors that can be used for improved disease detection and drug delivery. The nanomachines demonstrate the potential for early diagnosis and targeted release of drugs within patients, resulting in fewer side effects.
Researchers found high levels of activated Notch in tumor endothelium, promoting cancer cell invasion into bloodstream and forming lung metastases. Blocking Notch with antibodies reduced metastasis and immune cell invasion.
Scientists have identified a metabolic weakness in triple-negative breast cancer cells that may be exploited to quell their resistance to chemotherapy. Targeting this pathway could lead to increased cancer cell death and improved treatment outcomes.